Asthma control with ICS-formoterol reliever versus maintenance ICS and SABA reliever therapy: a post hoc analysis of two randomised controlled trials

BACKGROUND: In randomised controlled trials, as-needed inhaled corticosteroid (ICS)-formoterol reliever therapy reduces severe exacerbation risk compared with maintenance ICS plus short-acting beta(2)-agonist (SABA) reliever in adolescent and adult asthma, but results in slightly worse control of as...

Descripción completa

Detalles Bibliográficos
Autores principales: Hatter, Lee, Houghton, Claire, Bruce, Pepa, Holliday, Mark, Eathorne, Allie, Pavord, Ian, Reddel, Helen K, Hancox, Robert J, Braithwaite, Irene, Oldfield, Karen, Papi, Alberto, Weatherall, Mark, Beasley, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Asthma
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422833/
https://www.ncbi.nlm.nih.gov/pubmed/36007980
http://dx.doi.org/10.1136/bmjresp-2022-001271

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422833/
https://www.ncbi.nlm.nih.gov/pubmed/36007980
http://dx.doi.org/10.1136/bmjresp-2022-001271

Ejemplares similares